Gabapentin Capsule
Product Images NDC 70518-4742

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (02ae9973 70b1 4bcb A7aa E48351906e74 01)

An illustration showing the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a gender adjustment factor.*

FDA Label Image

Figure1 (02ae9973 70b1 4bcb A7aa E48351906e74 02)

Chemical structure of the active ingredient Gabapentin, showing its cyclohexane ring with attached amine and carboxyl groups.*

FDA Label Image

Image 1 (02ae9973 70b1 4bcb A7aa E48351906e74 03)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores on a scale from 0 to 10. Two phases are noted: a 4-week dose titration period followed by a 4-week fixed dose period. The graph shows a decrease in pain scores for Gabapentin over time, while placebo scores remain relatively stable.*

FDA Label Image

Image 2 (02ae9973 70b1 4bcb A7aa E48351906e74 04)

A line graph depicting mean pain scores over a 7-week period. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The study includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreasing mean pain scores throughout the timeline, with Gabapentin groups showing lower pain scores than placebo.*

FDA Label Image

Image 3 (02ae9973 70b1 4bcb A7aa E48351906e74 05)

A bar graph titled 'Figure 3. Proportion of Responders (patients with a 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates between placebo (PBO) and two dosages of Gabapentin (GBP 1800 and GBP 2400) across two studies. The vertical axis shows percentage response from 0% to 100%, and the bars indicate higher response percentages with Gabapentin versus placebo in both studies.*

FDA Label Image

Image 4 (02ae9973 70b1 4bcb A7aa E48351906e74 06)

A scatter plot graph displaying the difference percentage on the y-axis versus the daily dose in milligrams on the x-axis. The graph compares data points from three studies labeled as Study a (black squares), Study b (gray squares), and Study c (white squares) at daily doses of approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

Mm1 (Gabapentin 100mg 70518 4742 00)

Gabapentin Capsule 100 mg oral capsules, 100 count per box. The label shows the product as repackaged by RemedyRepack Inc., with the manufacturer listed as Strides Pharma Inc., Lambertville, NJ. The label includes storage instructions, quantity, and NDC number 70518-4742-00.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Capsule 100 mg in a single capsule quantity. The label shows the drug name, strength, and routing form as oral capsules. It is repackaged by RemedyRepack Inc., located in Indiana, PA. Manufacturer information includes Strides Pharma Inc., Lambertville, NJ. The label includes storage instructions and a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.